Literature DB >> 32454632

The Role of Secondary Metabolites on Gynecologic Cancer Therapy: Some Pathways and Mechanisms.

Mürşide Ayşe Demirel1, İpek Süntar2.   

Abstract

Gynecologic cancers are among the most common cancers in humans and animals. Treatment success depends on several factors including stage at diagnosis, tumor type, origin and metastasis. Currently, surgery, chemotherapy, and radiotherapy are preferred in the treatment of these cancers. However, many anticarcinogenic drugs can cause severe adverse effects and also the expected response to treatment may not be obtained. In recent studies, the importance of the relationship between cancer and inflammation has been emphasized. Therefore, several phytochemicals that exhibit beneficial bioactive effects towards inflammatory pathways were proven to have anticarcinogenic potential for gynecologic cancer therapy. This review summarizes the role of inflammatory pathways in gynecologic cancers and effective secondary metabolites for cancer therapy. ©Copyright 2017 Turk J Pharm Sci, Published by Galenos Publishing House.

Entities:  

Keywords:  Gynecologic cancers; inflammation; pathway; phytoconstituents; secondary metabolites

Year:  2017        PMID: 32454632      PMCID: PMC7227928          DOI: 10.4274/tjps.49368

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  131 in total

1.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.

Authors:  Margit A Huber; Ninel Azoitei; Bernd Baumann; Stefan Grünert; Andreas Sommer; Hubert Pehamberger; Norbert Kraut; Hartmut Beug; Thomas Wirth
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 2.  Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning.

Authors:  Bharat B Aggarwal; Shishir Shishodia
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

3.  Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer.

Authors:  Mi-Kyung Kim; Kidong Kim; Jae Yong Han; Jeong Mook Lim; Yong Sang Song
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

Review 4.  Canine mammary tumours, an overview.

Authors:  N Sleeckx; H de Rooster; E J B Veldhuis Kroeze; C Van Ginneken; L Van Brantegem
Journal:  Reprod Domest Anim       Date:  2011-06-06       Impact factor: 2.005

5.  Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer.

Authors:  M E Bracke; H T Depypere; T Boterberg; V L Van Marck; K M Vennekens; E Vanluchene; M Nuytinck; R Serreyn; M M Mareel
Journal:  J Natl Cancer Inst       Date:  1999-02-17       Impact factor: 13.506

6.  Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration.

Authors:  Y Arai; S Watanabe; M Kimira; K Shimoi; R Mochizuki; N Kinae
Journal:  J Nutr       Date:  2000-09       Impact factor: 4.798

7.  Antiproliferation effect of Rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro.

Authors:  Joseph Tai; Susan Cheung; Matthew Wu; David Hasman
Journal:  Phytomedicine       Date:  2012-02-09       Impact factor: 5.340

8.  Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats.

Authors:  B L Kasiske; M P O'Donnell; H Lee; Y Kim; W F Keane
Journal:  Kidney Int       Date:  1991-06       Impact factor: 10.612

9.  Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells.

Authors:  Eun Jeong Choi; Gun-Hee Kim
Journal:  J Nutr Biochem       Date:  2008-07-24       Impact factor: 6.048

10.  Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway.

Authors:  Haizhi Huang; Allen Y Chen; Xingqian Ye; Bingyun Li; Yon Rojanasakul; Gary O Rankin; Yi Charlie Chen
Journal:  Int J Oncol       Date:  2015-08-25       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.